Acute lymphoblastic leukemia

Researchers are testing a CAR-T therapy called pCAR-19B in people with CD19-positive B-cell acute lymphoblastic leukemia that has relapsed or stopped responding to standard treatment. Participants receive an intravenous infusion of their own immune cells, which have been engineer…

This trial tests different ways to prepare children and adolescents with acute lymphoblastic leukemia for a stem cell transplant. The goal is to see whether a conditioning regimen without total body irradiation works as well as one with it, and to find the best approach for diffe…

This trial is testing whether a treatment plan tailored to each child's genetic risk can improve outcomes for relapsed acute lymphoblastic leukemia. Children and young adults up to age 22 whose leukemia has returned in the bone marrow receive a combination of chemotherapy drugs, …

This phase 2 trial tests whether adding dasatinib and blinatumomab to standard chemotherapy can improve outcomes for children aged 1 to 19 with very high-risk acute lymphoblastic leukemia. The study focuses on patients with specific genetic markers or who did not respond to initi…

This trial tests whether using advanced genetic testing (NGS) to measure leftover cancer cells after initial treatment can help doctors tailor chemotherapy for children with standard-risk acute lymphoblastic leukemia. Around 116 children aged 1 to 10 will receive a standard chemo…

This phase 2 trial tests whether adjusting chemotherapy and using stem cell transplants based on each infant's genetic profile can improve survival. Infants under one year old with newly diagnosed leukemia receive a risk-stratified treatment plan. The study aims to see if this pe…

This large trial is testing whether adding the targeted drugs blinatumomab or venetoclax to standard chemotherapy can improve survival and reduce side effects in children with intermediate- or high-risk B-cell acute lymphoblastic leukemia (ALL). The study compares different sched…

This study tests whether giving donor white blood cells (lymphocytes) soon after a stem cell transplant can lower the chance of cancer returning in people with high-risk blood cancers like leukemia or lymphoma. Participants receive chemotherapy, a stem cell transplant, and then a…

This early-phase trial tests a new treatment called TSLPR-CART for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified in a lab to target a protein called TSLPR found on …

This early-stage trial is testing whether two drugs that lower metal levels in the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. The study will enroll 58 adults and aims to find the safest dose and check f…

This early-phase trial tests a personalized treatment for people with blood cancers like leukemia. Doctors take a patient's own T cells, modify them in the lab to recognize unique cancer mutations, and infuse them back after a short course of chemotherapy. The goal is to see if t…

This study tests an oral drug called revumenib in people with certain types of leukemia that have relapsed or not responded to standard therapy. The trial has two parts: first, finding the best dose, then testing that dose in four groups based on leukemia type. About 447 particip…

This early-phase trial is testing a combination of two drugs—Hyper-CVAD chemotherapy and venetoclax—in 22 children and young adults whose leukemia has returned or not responded to treatment. The main goal is to find a safe dose and monitor side effects. If the combination proves …

This study tests whether using stem cells from both a half-matched family donor and a cord blood donor can improve survival without cancer returning. It is for people with certain high-risk blood cancers like leukemia or myelodysplastic syndromes. The approach aims to control the…

This phase 3 trial is testing a CAR-T cell therapy called tisagenlecleucel that didn't quite meet commercial release standards. It's for people with B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma who have no other approved options. The study will check if th…

This early-phase trial is testing whether a long-acting antibiotic called dalbavancin, given once every 28 days along with a short course of oral antibiotics, can prevent serious bloodstream infections in children and young adults with high-risk leukemia. The study will enroll 29…

This early-phase trial tests whether giving patients a special infusion of donor immune cells (with certain T and B cells removed) after a stem cell transplant is safe and can help prevent their blood cancer from coming back. The study enrolls high-risk patients with hard-to-trea…

This study tests a new drug called asciminib, given with chemotherapy and later with another drug (blinatumomab), in children, teens, and young adults up to age 30 who have a type of leukemia (Ph+ or Ph-like ALL) that has come back or not responded to treatment. The goal is to fi…

This study is testing whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) while still being effective. The trial involves 260 adults with b…

This study tests whether a second type of CAR T-cell therapy, targeting CD22, can extend remission in people with B-cell acute lymphoblastic leukemia who have no signs of cancer after initial CD19 CAR T-cell treatment. About 20 children, adolescents, and adults will receive the m…

This study tests a standardized, optimized approach to cord blood transplantation for adults with high-risk blood cancers like leukemia and lymphoma. The method includes specific chemotherapy, radiation, and stem cell dosing, followed by careful monitoring. Researchers hope to im…

This Phase 1 trial is testing a new type of immunotherapy for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not gone away. The treatment uses the patient's own T cells, which are modified in the lab to recognize and attack leukem…

This phase 1 study is testing a combination of three drugs—ziftomenib, venetoclax, and azacitidine—in children and young adults (ages 2 to 21) with acute leukemia that has returned or not responded to treatment. The main goal is to find the safest dose of ziftomenib when given wi…

This early-stage trial tests a new antibody drug called 4A10 in 24 people with relapsed or hard-to-treat acute lymphoblastic leukemia or lymphoblastic lymphoma. 4A10 targets a protein on cancer cells to block growth signals and help the immune system attack them. The main goal is…

This study tests a specially engineered donor graft called Orca-Q in children and young adults with blood cancers who need a stem cell transplant. The graft is designed to help the new cells take hold and reduce complications. The trial is currently on hold, but aims to enroll 40…

This early-phase trial tests whether giving a second type of CAR T cell therapy (targeting CD22) after the standard CD19 CAR T therapy is safe and feasible for children and young adults with relapsed or hard-to-treat B-cell leukemia. About 20 participants will receive the standar…

This early-stage trial tests a new type of cell therapy for children and young adults up to age 21 with a form of leukemia (CD19-positive) that has returned or not responded to treatment. The therapy uses immune cells from a family donor that are engineered in a lab to recognize …

This study tests a new oral drug called bleximenib for people with acute leukemia that has come back or not responded to treatment. The drug targets specific genetic changes in the cancer cells. The trial has two phases: first to find the safest dose, then to see how well it work…

This early-phase study tests a new type of CAR-T cell therapy for people with certain blood cancers (like leukemia and lymphoma) that have not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and attack cancer cells. The main goa…

This early-phase study tests the drug TURALIO (pexidartinib) in people aged 3 to 35 whose cancer has not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors or control leukemia. Participants take a daily capsule for up to 2 years, wit…

This study tests a new drug called MK-1045 (CN201) in people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or stopped responding to treatment. The trial has two parts: first, finding a safe dose, and then checking how well the drug works. Ab…

This study tests a CAR T-cell therapy called obe-cel in adults with B-cell acute lymphoblastic leukemia (ALL) whose cancer is in complete remission with no detectable cancer cells. The goal is to see if obe-cel can prevent the cancer from coming back. About 40 participants will r…

This study tests a new treatment called CTD402 for people with T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (T-LBL) that has come back or not responded to other treatments. Participants receive one infusion of CTD402 and are monitored for safety and how w…

This early-stage trial is testing a new combination of chemotherapy drugs (thiotepa, busulfan, and fludarabine) followed by a stem cell transplant for people with certain blood cancers like leukemia and myelodysplastic syndrome. The goal is to see if this approach can reduce the …

This study is for adolescents and young adults (ages not specified) with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). Researchers want to see if a specific combination of chemotherapy drugs plus the immunotherapy blinatumomab helps more pat…

This study tests a drug called inotuzumab ozogamicin (Besponsa) against standard chemotherapy for children aged 1 to 17 with high-risk B-cell acute lymphoblastic leukemia that has returned after initial treatment. The goal is to see if the targeted drug can clear more cancer cell…

This study tests MedSupport, a program designed to help families of children with acute lymphoblastic leukemia give their child daily oral chemotherapy at home. Missing even a few doses can raise the risk of cancer returning. The program uses a special pill bottle cap that tracks…

This Phase 2 trial is testing whether a CAR T-cell therapy called obecabtagene autoleucel (obe-cel) can help control newly diagnosed, high-risk B-cell acute lymphoblastic leukemia (ALL) after initial treatment. The study will enroll 30 adults with high-risk features who are in fi…

This study is testing a new, comprehensive treatment plan for children and young adults (ages 0-45) newly diagnosed with acute lymphoblastic leukemia (ALL). It combines the best approaches from previous successful treatments to improve survival and reduce side effects. The study …

This early-phase trial is testing whether adding a patient's own blood stem cells to standard CAR T-cell therapy is safe and doable for people with relapsed or refractory blood cancers like lymphoma, leukemia, and myeloma. Twenty participants will receive their own stem cells 10 …

This study is testing a powerful chemotherapy regimen originally designed for children, combined with the targeted drug venetoclax and immunotherapy, in adults aged 14 to 60 with a certain type of acute lymphoblastic leukemia (ALL). The goal is to see if this approach can achieve…

This phase II trial is testing a combination of six chemotherapy drugs (clofarabine, etoposide, cyclophosphamide, liposomal vincristine, dexamethasone, and bortezomib) in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, or related cancers that have come back or…

This early-phase trial tests the safety of a new drug called karonudib in up to 9 adults with blood cancers like leukemia who have no standard treatment options left. The study aims to find a safe dose and look for any signs that the drug works. It is too early to know if karonud…

This study is testing whether a personalized cell therapy called MB-CART19.1 can be manufactured right at the hospital for children and adults with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments. The therapy uses the patient's own i…

This early-phase trial tests whether adding a radioactive antibody (225Ac-DOTA-daratumumab) to standard chemotherapy and targeted radiation can safely improve the conditioning regimen before a donor stem cell transplant. The study includes 15 adults with high-risk acute myeloid l…

This phase 2 trial tests whether giving patients their own personalized natural killer (NK) cells after chemotherapy and a cord blood transplant can help kill any remaining cancer cells. The study includes 100 people with various blood cancers like leukemia, lymphoma, and multipl…

This study tests a new type of CAR T-cell therapy that targets two proteins, CD19 and CD22, on cancer cells. It is for children and young adults aged 3 to 39 with B-cell cancers like leukemia or lymphoma that have not been cured by standard treatments. Participants receive their …

This program gives patients with certain blood cancers access to Orca-T, a donor stem cell therapy, when the commercial version cannot be used. It is for people who have no other treatment options. The program monitors safety but does not test if the therapy works.

This study is testing a new combination of low-intensity chemotherapy and targeted immunotherapy for people newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Participants will receive a third-generation TKI drug (olverembatinib) and may…

This study tests the drug ponatinib in children aged 1 to 18 with advanced leukemias, lymphomas, or solid tumors that have come back or not responded to standard treatment. The goal is to find safe doses and see if the drug can shrink tumors or improve blood counts. About 70 chil…

This study tests a special cord blood transplant for people with high-risk blood cancers like leukemia and lymphoma. Participants get chemotherapy and radiation before the transplant to kill cancer cells and prepare the body. After the transplant, drugs are given to prevent the n…

This early-phase study tests whether specially engineered donor immune cells (TSC-100 or TSC-101) can safely reduce the risk of cancer returning after a stem cell transplant. About 75 adults with acute myeloid leukemia, myelodysplastic syndromes, or acute lymphoblastic leukemia w…

This early-phase study is testing an experimental oral drug called AZD3632 in about 84 people with advanced blood cancers (acute leukemias or myelodysplastic syndromes) that have certain genetic changes. The main goals are to check the drug's safety and find the right dose, while…

This study tests whether giving two targeted immunotherapy drugs (inotuzumab and blinatumomab) together at the start of treatment can eliminate leukemia cells more effectively than standard chemotherapy in children and young adults (ages 1-18) with newly diagnosed B-cell acute ly…

This trial tests a therapy where a person's own immune cells are modified to attack cancer cells carrying a protein called CD19. It is for adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or B-cell acute lymphoblastic leukemia that has not responded to standa…

This study is testing a drug called inotuzumab ozogamicin, which is like a smart bomb that targets and kills leukemia cells, combined with low-intensity chemotherapy. The goal is to find the best dose and see if this combo works better than standard treatments for patients with a…

This trial investigates a personalized cell therapy called CAR-T for children and young adults (ages 5–50) with B-cell acute lymphoblastic leukemia that has relapsed or not responded to standard treatment. The therapy involves collecting a patient's own immune cells, engineering …

This study tests a drug called blinatumomab in infants under 1 year old who have a specific, hard-to-treat type of leukemia (KMT2A-rearranged). The goal is to improve how long these babies stay cancer-free and to help them live longer. About 160 infants from around the world will…

This study tests whether giving children with leukemia a special type of donor immune cell (CD45RA-depleted) after a stem cell transplant can help their immune system recover faster and lower the risk of serious viral or fungal infections. The trial enrolls 50 children under 25 w…

This study tests a stem cell transplant using a reduced-intensity conditioning regimen (lower doses of chemotherapy and radiation) followed by a donor stem cell infusion. The goal is to treat various blood cancers and blood disorders while lowering the risk of graft-versus-host d…

This study provides unlicensed cord blood units for transplant to children and adults with blood cancers, immune disorders, and other serious diseases. The goal is to see how well patients recover their white blood cells after the transplant. By making more cord blood units avail…

This trial investigates CRC01, a therapy made from a patient's own immune cells that are genetically modified to recognize and attack cancer cells. It is for adults with large B-cell lymphoma or B-cell acute lymphoblastic leukemia that has returned or not responded to previous tr…

This study tests whether adding the drug blinatumomab along with a low dose of donor immune cells (called donor lymphocyte infusion) can help prevent relapse in people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) who have already had a stem cell transplant. The trea…

This study tests a new way to prepare donor stem cells (called Orca-Q) for people with blood cancers like leukemia or MDS who need a transplant. The goal is to see if this engineered graft is safe and helps the body accept the new cells with fewer complications. About 300 partici…

This phase 2 trial tests whether adding vedolizumab to standard drugs (cyclophosphamide and tacrolimus) can prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers like leukemia and myelodysplastic syndrome. GVHD occurs when donor immu…

This early-stage trial is testing whether adding the drug ruxolitinib (Jakafi) to standard chemotherapy is safe for adolescents and young adults (ages 12-39) newly diagnosed with Ph-like acute lymphoblastic leukemia (ALL), an aggressive subtype. The study will enroll 15 participa…

This Phase 2 trial is testing a stem cell transplant from a donor for people with various blood cancers and bone marrow disorders. The transplant uses strong chemotherapy or radiation to wipe out the diseased marrow, then replaces it with healthy donor cells. A new combination of…

This early-phase trial tests a cell therapy called Orca-T combined with standard drugs to prevent graft-versus-host disease (GVHD) in 24 adults with advanced blood cancers (like leukemia or MDS) receiving stem cell transplants from partially matched donors. The main goal is to se…

This study tests a radioactive antibody (211At-BC8-B10) that seeks out and attacks cancer cells, followed by a donor stem cell transplant for people with high-risk leukemia or myelodysplastic syndrome (MDS) that has returned or not responded to treatment. The goal is to find the …

This study tests whether combining two drugs, revumenib and mezigdomide, is safe for people with specific types of acute leukemia that have returned or not responded to prior therapy. About 52 participants aged 12 and older will take part. The goal is to find the best dose and se…

This study is testing a new approach for people with high-risk acute leukemias or myelodysplastic syndrome. Before a donor stem cell transplant, patients receive a radioactive antibody (211At-BC8-B10) designed to target and kill cancer cells while sparing healthy tissue. The goal…

This study tests whether combining two drugs, blinatumomab and asciminib, can help control Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The trial enrolls 40 adults who are not good candidates for strong chemotherapy. Researchers will monitor safety and…

This study tests a new chemotherapy-free treatment for adults with a specific type of leukemia called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The treatment combines three drugs: inotuzumab ozogamicin, dasatinib, and dexamethasone. The goal is to s…

This study tests a weight loss program for adult survivors of childhood acute lymphoblastic leukemia (ALL) who are overweight or have obesity. Participants receive a weekly injection of tirzepatide plus remote, supervised resistance exercise three times a week for 28 weeks. The g…

This study tests a stem cell transplant method that removes certain immune cells (T-cells and B-cells) from the donor cells. The goal is to reduce graft-versus-host disease, a serious complication where donor cells attack the patient's body. The trial includes 20 children and you…

This study tests a new treatment plan for infants (up to 12 months old) with a type of leukemia called acute lymphoblastic leukemia. The goal is to see if adding an immunotherapy drug called blinatumomab can better clear leukemia cells that remain after initial treatment. About 9…

This early-stage trial tests a new type of cell therapy for people with certain blood cancers (like lymphoma, leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are genetically modified to recognize and …

This study tests a stem cell transplant from half-matched (haploidentical) donors for people with various blood cancers. Before the transplant, patients receive chemotherapy and low-dose radiation to prepare their body. The goal is to replace diseased bone marrow with healthy don…

This early-stage trial is testing a new type of immunotherapy for children and young adults with a high-risk or relapsed form of acute lymphoblastic leukemia. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack leukemia cells tha…

This study tests a combination of two drugs, blinatumomab and ponatinib, along with standard chemotherapy, in people with a specific type of acute lymphoblastic leukemia (ALL) that has a genetic change called the Philadelphia chromosome. The goal is to see if this mix can better …

This early-phase study tests a new type of immune cell therapy (CAR T cells) that targets two proteins, CD19 and CD22, on leukemia cells. It is for children and young adults up to age 21 whose leukemia has returned or not responded to standard treatments. The main goal is to find…

This early-phase trial tests a new immunotherapy for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses specially engineered donor T cells designed to recognize and attack a protein called HA-1 found …

This early-phase trial is testing a new type of CAR-T cell therapy, called CD19-CAR.p40-T, in 10 adults with B-cell lymphoma, acute lymphoblastic leukemia, or acute myeloid leukemia that has come back or not responded to treatment. Participants receive chemotherapy followed by an…

This study is for adults aged 14 to 60 with a specific, high-risk type of acute lymphoblastic leukemia called Ph-like ALL. Researchers are testing whether adding targeted drugs (olverembatinib or gecacitinib) and venetoclax to standard chemotherapy can help more patients achieve …

This pilot study tests a stem cell transplant method that removes specific immune cells (alpha/beta T cells and B cells) from the donor cells before transplant. The goal is to reduce the risk of graft-versus-host disease, a serious complication, while still allowing the transplan…

This study tests whether a cord blood transplant can help children and young adults (up to age 26) with blood cancers like leukemia and lymphoma. Participants receive the transplant as their first or second treatment. The main goal is to see how many are cancer-free one year afte…

This study tests a new type of CAR-T cell therapy for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. The therapy uses donor immune cells that are modified to target cancer cells and last longer in the body. The goal is to…

This phase II trial tests different drug combinations to prevent graft-versus-host disease (GVHD) in 400 blood cancer patients receiving stem cell transplants from unrelated donors. Participants will receive either thymoglobulin or a combination of cyclophosphamide with other imm…

This early-stage study tests a new oral drug, LP-118, in up to 100 adults with blood cancers like lymphoma, leukemia, or myeloma that returned or didn't respond to prior therapy. The main goals are to find the safest dose and see if the drug can shrink tumors or slow the disease.…

This study looks at whether menin inhibitors can help prevent leukemia from coming back in patients who have had a stem cell transplant. About 20 adults with certain genetic types of acute leukemia will take these drugs as maintenance therapy. Researchers will track how many pati…

This phase 3 study tests whether adding the experimental drug olverembatinib to standard chemotherapy works better than the usual targeted therapy (a TKI) plus chemotherapy for people newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Th…

This study looks at how well CAR-T cell therapy works for people with certain blood cancers like lymphoma and leukemia. Researchers will track how the modified immune cells grow and last in the body after infusion. The goal is to see if this treatment is effective in real-world s…

This early-phase trial tests whether giving special immune cells (CMV-specific CD19-CAR T cells) along with a vaccine (CMV-MVA triplex) is safe and feasible for 15 people with high-risk acute lymphoblastic leukemia after a stem cell transplant. The modified T cells are designed t…

This study tests whether a mobile app can help children with acute lymphoblastic leukemia (ALL) keep their white blood cell counts in a healthy range during maintenance therapy. About 100 children who are already doing well on the app will be randomly assigned to continue using i…

This early-phase trial tests a stem cell therapy called Orca-T combined with targeted radiation and chemotherapy for people aged 60-75 with acute leukemias or myelodysplastic syndrome. The goal is to see if this approach is safe and can reduce side effects while effectively treat…

This phase 2 trial tests an optimized cord blood transplant for 35 patients with high-risk blood cancers (like leukemia) who relapsed after their first stem cell transplant. Participants receive chemotherapy followed by a cord blood infusion, plus drugs to prevent rejection. The …

This program provides early access to CTL019, a cell therapy that reprograms a patient's own immune cells to attack cancer. It is for people with lymphoma or leukemia who have no other treatment choices and cannot join a clinical trial. The goal is to offer a potential benefit wh…

This study tests a behavioral program called CareMeds that teaches parents skills to help their young children (ages 3-9) with acute lymphoblastic leukemia take oral chemotherapy at home. Researchers will enroll 100 families across two cities to see if the program is feasible and…

This early-phase trial tests whether two drugs, ruxolitinib and abatacept, can prevent graft-versus-host disease (GVHD) and cytokine release syndrome in people receiving stem cell transplants from half-matched donors. About 41 adults with blood cancers will take these drugs aroun…

This study tests whether a new chemotherapy combination (TmBU) works better than the standard one (mBUCY) before a stem cell transplant in people with high-risk or hard-to-treat acute leukemia. About 48 patients aged 65 or younger will be randomly assigned to one of the two regim…

This study tests whether giving a chemotherapy drug (methotrexate) into the spinal fluid before and during blinatumomab treatment can prevent nerve-related side effects in adults with acute lymphoblastic leukemia. The trial enrolls 20 people receiving their first cycle of blinatu…

This study tests whether a drug called sargramostim can help restore white blood cells as quickly as the standard drug (G-CSF) after a half-matched stem cell transplant for blood cancers, while possibly lowering the risk of serious infections. About 38 adults with blood cancers l…

This early-phase study tests a new automated method (CliniMACS Prodigy) to select CD34 stem cells for patients with blood cancers who need a stem cell boost or second transplant. The goal is to reduce the risk of severe graft-versus-host disease (GVHD) while improving blood cell …

This expanded access study provides brexacabtagene autoleucel (Tecartus) to patients with mantle cell lymphoma or acute lymphoblastic leukemia whose commercially manufactured batch did not meet release specifications but still meets internal clinical trial criteria. Eligible pati…

This study tests whether adding a precise, targeted form of radiation to the standard chemotherapy and stem cell transplant can kill more cancer cells in the bone marrow and reduce the chance of relapse. About 27 adults with acute leukemia or myelodysplastic syndrome (MDS) will r…

This trial tests whether a lower dose of total body irradiation (200 cGy) before a bone marrow transplant works as well as a standard higher dose (400 cGy) for people with acute leukemia. The goal is to see which dose leads to fewer severe side effects like graft-versus-host dise…

This study tests a special stem cell transplant for children and adults with blood cancers like leukemia. The transplant uses stem cells that have had certain immune cells removed to lower the risk of graft-versus-host disease, a serious complication. About 70 participants will r…

This early-stage trial is testing a new type of immunotherapy for people with CD30-positive blood cancers that have come back or not responded to treatment. The therapy uses a patient's own immune cells, which are collected, modified with a special antibody, and then given back t…

This phase 2 trial tests KTE-X19 (Tecartus), a personalized CAR T-cell therapy, in adults with B-cell acute lymphoblastic leukemia who are in remission but still have tiny amounts of cancer cells (minimal residual disease). The goal is to see if this treatment can clear those lef…

This study tests an experimental drug called LBS-007 in adults with acute leukemias (AML or ALL) that have returned or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can control the disease. About 90 participants will receive the …

This study tests a personalized cell therapy for children and young adults with a type of leukemia that has come back or not responded to standard treatment. Doctors collect the patient's own immune cells, modify them to recognize and attack cancer cells, and give them back after…

This study tests a new oral drug called enzomenib (DSP-5336) in people with acute leukemia and certain other blood cancers that have not responded to standard treatments. The trial has two phases: first, finding the safest dose, and then checking how well it works alone or combin…

This early-phase trial tests whether giving patients extra gamma delta T-cells—a type of immune cell that can kill cancer—after a half-matched bone marrow transplant can improve outcomes. The study includes up to 38 adults with leukemia or myelodysplastic syndromes. The goal is t…

This study tests a sequence of two immunotherapy drugs, blinatumomab and inotuzumab ozogamicin, in people with B-cell acute lymphoblastic leukemia (B-ALL). It includes newly diagnosed patients who are older or too frail for intensive chemotherapy, as well as those whose cancer ha…

This phase 2 trial is testing a new combination of chemotherapy, radiation, and immune-suppressing drugs for people aged 18-65 with blood cancers who need a stem cell transplant. The goal is to see if this regimen improves survival one year after transplant. About 209 participant…

This study tests whether adding the drug bortezomib to standard chemotherapy helps more children with high-risk relapsed acute lymphoblastic leukemia (ALL) achieve remission. About 250 children under 18 with a first relapse of ALL will be randomly assigned to receive either stand…

This study tests a new drug called LP-118 combined with three existing cancer medicines (ponatinib, vincristine, and dexamethasone) in adults with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to treatment. The goal is to…

This study tests whether new drug combinations can better prevent graft-versus-host disease (GVHD) in people with blood cancers who receive a stem cell transplant from a mismatched unrelated donor. About 358 participants will get either the standard GVHD prevention or one of two …

This early-stage trial is testing an oral drug called BY002 in 18 adults with relapsed or refractory acute leukemia that has specific genetic changes (KMT2A rearrangements or NPM1 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shr…

This early-phase study tests a new "universal" CAR-T cell therapy (CT1190B) for people aged 12-75 with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatment. The therapy is made from donor cells, so it can be given without needing the patie…

This study tests a cord blood transplant in children and young adults (up to age 21) with life-threatening blood cancers or non-cancer blood disorders who do not have a matched family donor. The goal is to see if this approach lowers the risk of death from treatment one year afte…

This early-phase trial is testing whether adding the drug venetoclax to standard chemotherapy is safe and tolerable for children, adolescents, and young adults with high-risk blood cancers like MDS, AML, and ALL. About 30 participants will receive different combinations of chemot…

This early-stage trial tests a new type of immunotherapy (CAR T cells) in adults with B-cell acute lymphoblastic leukemia (B-ALL) who still have tiny amounts of cancer cells after their first round of treatment. The goal is to see if the therapy is safe and can eliminate these le…

This phase II trial is testing two different methods to reduce graft-versus-host disease (GVHD) in patients with acute leukemia or myelodysplastic syndrome (MDS) who are receiving a donor stem cell transplant. One method removes certain immune cells from the donor cells before tr…

This study tests two approaches for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. One group gets a sequence of two types of CAR T-cells (targeting CD19 and CD22), while the other gets one type of CAR T-cell followed by a stem ce…

This study tests a new treatment called CD5 CAR T-cells for people with T-cell cancers (like certain leukemias) that have returned or not responded to standard care. The treatment uses a patient's own immune cells or cells from a donor, which are modified in a lab to recognize an…

This early-phase trial tests a two-step approach for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. First, patients receive donor-derived CD19 CAR T cells, then a stem cell transplant from the same donor, followed by donor-derive…

This early-phase study is testing whether adding a drug called calaspargase pegol to standard chemotherapy (Hyper-CVAD) is safe and tolerable for young adults newly diagnosed with acute lymphoblastic leukemia (ALL). About 7 participants will receive the combination after completi…

This early-phase trial tests a drug called revumenib in people with acute leukemia who have had a stem cell transplant. The drug targets a protein that helps leukemia cells grow. The study will check safety, find the best dose, and see if it can stop the cancer from coming back. …

This study tests a new treatment plan for children with acute lymphoblastic leukemia (ALL) in low- and middle-income African countries. The plan uses stronger chemotherapy for high-risk cases and aims for an 85% remission rate. Researchers will track whether the drugs are availab…

This study tests whether adding cytokine-induced killer (CIK) cells can prevent CAR-T cells from wearing out too early in children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 213 participants will be randomly assigned to receive eith…

This early-phase study tests whether stem cells from donated umbilical cord blood can safely help people whose blood counts stay dangerously low after CAR-T therapy. The trial will enroll 15 adults with leukemia, lymphoma, or myeloma. Participants receive weekly stem cell infusio…

This study tests a personalized cell therapy called CAR T-cells for people with relapsed or hard-to-treat lymphoma or acute lymphoblastic leukemia (ALL). The therapy involves collecting a patient's own immune cells, modifying them to recognize and attack cancer cells, and infusin…

This study tests whether adding newer antibody-based drugs to standard chemotherapy can improve survival and reduce the need for stem cell transplants in adults with acute lymphoblastic leukemia (ALL). About 1,200 patients aged 18–65 with newly diagnosed ALL will be assigned to o…

This early-phase trial tests a new type of CAR T-cell therapy for people with acute lymphoblastic leukemia (ALL) that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and attack l…

This study tests a drug called tafasitamab in children aged 3 to 17 with B-cell leukemia that has come back or not responded to treatment. The drug is an antibody that helps the immune system find and kill leukemia cells. The trial has two parts: first, finding the best dose, and…

This phase 2 trial tests a personalized approach to stem cell transplants for people with blood cancers like leukemia and lymphoma. Instead of a one-size-fits-all chemotherapy and radiation regimen, doctors adjust the doses based on each patient's risk. The goal is to improve the…

This program offers early access to venetoclax, a targeted cancer pill, for people with certain blood cancers like leukemia or lymphoma who have no other good treatment options. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved in all…

This early-phase trial tests whether infusing specially designed immune cells can prevent blood cancer from coming back after a stem cell transplant. The cells target a specific protein (HLA-DPB1*04:01) found on many cancer cells and include a 'suicide switch' to turn them off if…

This study tests a new method to prevent graft-versus-host disease (GVHD) in children and young adults with high-risk blood cancers who need a stem cell transplant from a half-matched donor. The approach combines specially enriched donor immune cells with a stem cell graft that h…

This study is testing a new type of immunotherapy called CAR T cells for adults (ages 18-75) with a hard-to-treat blood cancer called acute lymphoblastic leukemia (ALL) that has come back or not responded to standard treatments. The treatment involves taking a patient's own immun…

This early-phase trial is testing a new drug called CG009301 in adults with blood cancers like leukemia that have returned or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can help. About 45 participants will receive the drug by …

This early-phase study tests whether a special cell therapy called T-allo10 can safely help rebuild the immune system in children and young adults (up to age 45) with blood cancers who have received a stem cell transplant. The treatment is given after the transplant to speed up r…

This early-stage trial is testing an experimental oral drug called MRX-2843 in adolescents and adults whose acute leukemia (AML, ALL, or mixed phenotype) has returned or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and s…

This study tests a new treatment for people with advanced B-cell lymphoma or leukemia that has returned or not improved after standard therapy. Researchers take a patient's own T-cells, add a special receptor (CAR) that targets the CD19 protein on cancer cells, and also add extra…

This study tests whether sulforaphane, a compound found in broccoli sprouts, can help blood cells recover faster after a cord blood transplant in adults with leukemia or related blood cancers. The trial will involve 36 patients and focus on safety and how quickly neutrophils (a t…

This early-phase trial is testing a new cell therapy called LV009 for people with certain blood cancers (lymphoma and leukemia) that have come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to target cancer cells. The main goal is to c…

This study is testing a combination of three drugs—venetoclax, cladribine, and low-dose cytarabine—in 36 people aged 15–70 with relapsed or refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL). The goal is to see how well the treatment shrinks o…

This early study tests a new treatment called LV009 injection in 10 adults whose blood cancers (certain types of lymphoma or leukemia) have returned or stopped responding to standard therapy. The main goal is to check if the treatment is safe. Participants receive the injection a…

This study tests a dose-adjusted chemotherapy regimen for adults with acute lymphoblastic leukemia who are too frail for standard treatment. The goal is to improve survival and reduce severe side effects. About 45 participants will receive an infusion-based therapy designed to be…

This study tests whether specially engineered immune cells (CAR-T cells) can treat adults with a specific, aggressive form of acute lymphoblastic leukemia that has a genetic marker called the Philadelphia chromosome. Fifty newly diagnosed patients will receive an infusion of thes…

This study tests whether a tailored exercise program combined with a dietary supplement called nicotinamide riboside (NR) can improve muscle mass, strength, and fitness in adolescents and young adults who had a bone marrow transplant for leukemia or other blood disorders. About 8…

This study tests a new treatment called CD7 CAR T-cell therapy for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells or cells from a donor, which are modified to find and attack cancer cells. The …

This study follows 40 people who received Miltenyi CAR T cell therapy at least one year ago for cancers like melanoma, lymphoma, or leukemia. Researchers will track side effects, cancer return, and overall health for years. The goal is to understand the long-term safety and effec…

This study tests a new type of CAR T-cell therapy that targets a protein called CD5 on cancer cells. It is for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses the patient's own immune cells or cells from a donor, which are …

This phase 2 trial tests the drug inotuzumab ozogamicin in 42 adults with B-cell acute lymphoblastic leukemia who have minimal residual disease (MRD) after a stem cell transplant. MRD means a few cancer cells remain undetectable by standard tests but can cause relapse. The drug a…

This study tests whether adding the drug ruxolitinib to the usual anti-rejection medicines (tacrolimus and methotrexate) can prevent graft-versus-host disease (GVHD) in children and young adults getting a stem cell transplant for leukemia or myelodysplastic syndrome. GVHD happens…

This phase 2 trial tests a two-step, lower-intensity transplant method for people with various blood cancers. The goal is to see if this gentler approach reduces the chance of dying from the transplant itself. About 63 participants will receive a combination of radiation, chemoth…

This early-phase trial tests a new type of stem cell transplant for children with blood cancers or solid tumors that have relapsed or not responded to standard treatment. Doctors use a half-matched donor's stem cells, specially filtered to remove certain immune cells, and give th…

This phase 2 trial tests whether a new way of giving anti-thymocyte globulin (ATG) along with standard drugs tacrolimus and methotrexate can prevent acute graft-versus-host disease (GVHD) after a stem cell transplant. The study enrolls 29 adults aged 18-60 with blood cancers who …

This phase 2 trial tests whether adding a low dose of venetoclax (a targeted drug) with itraconazole to standard chemotherapy can improve remission rates in people with relapsed or refractory acute lymphoblastic leukemia. The study enrolls 12 adults whose leukemia has returned or…

This study tests whether adding a targeted drug (like dasatinib or sorafenib) to standard chemotherapy helps people with newly diagnosed acute T-lymphocytic leukemia live longer. About 154 adults will be randomly assigned to get either chemo alone or chemo plus the targeted drug.…

This early study tests an experimental oral drug called HMPL-506 in about 132 adults with specific types of leukemia (AML or ALL) that have come back or not responded to treatment. The main goal is to check safety and find the right dose. Researchers will also look for signs that…

This early-phase study tests a personalized therapy where a patient's own immune cells are modified to recognize and attack cancer cells. It is for children and adults with certain blood cancers (like leukemia or lymphoma) that have not responded to standard treatments. The goal …

This study tests whether using a simple early warning score (NEWS) to quickly move high-risk blood cancer patients to the ICU can reduce deaths and organ failure. Over 2,200 adults receiving intensive chemotherapy or stem cell transplants will take part across ten hospitals. Half…

This study tests a new combination of drugs for children and young adults whose leukemia or lymphoma has returned or not responded to treatment. The drugs include trametinib (a targeted therapy) plus standard chemotherapy. The goal is to find the safest dose and see if the combin…

This trial tests a combination of dasatinib, venetoclax, and chemotherapy in children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). The study has two phases: first to find the safest dose, then to see how well it …

This study tests a combination of two targeted drugs (ruxolitinib and venetoclax) plus standard chemotherapy in children and young adults up to age 21 whose leukemia or lymphoma has returned or not responded to treatment. The goal is to find the safest dose and see how many patie…

This study looks at whether a wearable heart monitor and a symptom questionnaire can accurately detect autonomic dysfunction—a condition affecting heart rate and blood pressure control—in survivors of childhood leukemia and lymphoma. Researchers will compare these remote methods …

This study tests a new, high-resolution ultrasound technique called Ultrasound Localization Microscopy (ULM) to detect early kidney damage in children who have been treated for acute lymphoblastic leukemia (ALL). The method uses tiny bubbles (contrast agent) to see blood flow in …

Researchers are testing inotuzumab ozogamicin, an antibody-drug conjugate, in people with CD22-positive acute lymphocytic leukemia who have already had a stem cell transplant. The trial has two parts: a phase 1 portion to find the highest dose that is safe to give after transplan…

This study looks at whether a low dose of the antifungal drug liposomal amphotericin B can prevent serious fungal infections in adults with blood cancers or who have had stem cell transplants and have a prolonged low white blood cell count (neutropenia). The trial enrolls 30 pati…

This early-phase trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV) and prevent active infection after a half-matched stem cell transplant. About 46 people with various blood cancers will take part…

This phase 2 trial tests a vaccine called CMV-MVA Triplex, given to stem cell donors before they donate. The goal is to boost the donor's immunity against cytomegalovirus (CMV), which can then be passed to the transplant patient. Researchers hope this will prevent CMV infection i…

This study tests a 6-month virtual nutrition education program (PEDALL) to prevent overweight and obesity in children and teens with acute lymphoblastic leukemia (ALL) during maintenance chemotherapy. The program is offered in English and Spanish to 376 participants aged 5-21. Re…

This study tests a program called EASE that combines psychological support with regular symptom checks and early access to palliative care. Researchers want to see if it reduces traumatic stress and physical symptoms in people newly diagnosed with acute leukemia. Half of the 266 …

This study tests whether a non-invasive earbud that gently stimulates a nerve in the ear can help adult survivors of childhood leukemia who have trouble sleeping. Forty participants will be randomly assigned to receive either active or sham stimulation nightly for 2 to 8 weeks. T…

This study tests an online music therapy program that combines mindfulness and music to help people recovering from stem cell transplants for blood cancers. Researchers want to see if it can improve quality of life, reduce pain, fatigue, anxiety, and depression, and possibly spee…

This study tests whether a 9-week strength training program using resistance bands and body weight exercises is practical for children aged 6-21 newly diagnosed with acute lymphoblastic leukemia or lymphoblastic lymphoma. The program combines at-home exercises with optional Zoom …

This study tests whether daily or weekly text message reminders help adolescents and young adults (ages 15-39) with acute lymphoblastic leukemia (ALL) take their oral chemotherapy medications (mercaptopurine and methotrexate) more consistently during maintenance therapy. Particip…

This study tests a program called Nite2Day+ that uses mindfulness and sleep tips to help people with blood cancers sleep better and manage fatigue, stress, and pain. About 60 adults hospitalized for treatment will either get the program or standard care. The program includes a mo…

This pilot study tests whether a physical activity program can help children aged 5–17 with acute lymphoblastic leukemia maintain muscle strength and avoid frailty during early treatment. Kids who show signs of weakness after five weeks of chemotherapy are randomly assigned to ei…

This study tests a 12-week virtual buddy-movement therapy for children aged 5 to 12 who have finished treatment for acute lymphoblastic leukemia. The program pairs each child with a healthy buddy for twice-weekly movement sessions designed to improve motor skills, coordination, a…

This study tests whether regular massage therapy can improve sleep for children aged 12-21 who are hospitalized for cancer treatment or stem cell transplant. Seventy participants will either receive standard care or a 20-30 minute massage five days a week for three weeks. Sleep w…

This study tests whether online cognitive training and mindfulness can help children aged 8-18 who had leukemia and received intensive treatments like CAR-T therapy, chemotherapy, or a stem cell transplant. Forty participants will do brain exercises and mindfulness sessions from …

This study tests whether coloring mandalas for 30 minutes before intrathecal chemotherapy can lower anxiety and fear in children aged 4-12 with leukemia. Sixty children will be asked to color a mandala, and their fear and anxiety levels will be measured using standard scales. The…

This study looks at whether guided play sessions can help children aged 10 to 18 with leukemia handle pain and regulate emotions while receiving chemotherapy. Over 4 weeks, kids will take part in therapeutic play during their treatment. Researchers will measure changes in pain to…

This study tests if a home-based program of laughter and fun yoga can lower pain in children aged 2-10 with acute lymphoblastic leukemia who are receiving chemotherapy. Sixty participants will be randomly assigned to either the laughter and yoga program plus usual care, or usual …

This study tests whether regular blood and bone marrow tests using advanced DNA sequencing can better monitor children with B-cell acute lymphoblastic leukemia (B-ALL) after they achieve remission with CAR T therapy. The goal is to see if these tests can identify who is truly cur…

This study uses non-invasive MRI and MRS scans to measure how well muscle cells produce energy in adults who survived childhood acute lymphoblastic leukemia (ALL). Researchers will compare 60 survivors with low muscle mass to healthy volunteers. The goal is to understand why many…

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This study looks at whether a simple blood test can track how well treatment is working in children with acute lymphoblastic leukemia (ALL). Currently, doctors must take bone marrow samples to check for leftover cancer cells, which is invasive and painful. The researchers will co…

This study looks at the long-term health of people with Down syndrome who have been treated for acute leukemia. Researchers want to understand what chronic health problems survivors may face and what factors contribute to them. The goal is to create better follow-up care guidelin…

This study screens children and young adults up to age 22 whose leukemia has returned or is hard to treat. By testing their blood and bone marrow, doctors can identify specific genetic markers to match them with the most promising experimental treatments. The goal is to build a r…

This pilot study is for children and young adults (0-45 years) newly diagnosed with acute lymphoblastic leukaemia (ALL). It collects information on standard treatments already used in clinics to help prepare for future research trials. The study involves 500 participants and focu…

This study investigates whether a blood marker called anti-Müllerian hormone (AMH) can predict future infertility in children and adolescents who have undergone cancer treatment. Many young patients recover normal menstrual cycles or puberty after chemotherapy, but their ovarian …

This study follows children and young adults with acute lymphoblastic leukemia (ALL) who receive CAR-T cell therapy. The goal is to track how long these engineered immune cells persist in the body and identify factors that cause them to disappear. By understanding why CAR-T cells…

This study is a large registry that will collect medical information and biological samples from up to 10,000 adults with acute lymphoblastic leukemia (ALL) and related blood cancers. The goal is to track how patients are diagnosed, treated, and how they fare over time. By gather…

This early-stage study with 10 adults with acute leukemia looks at how the body absorbs, breaks down, and gets rid of the drug bleximenib. Participants take a radioactive version of the drug so researchers can track it in urine and stool. The goal is to understand the drug's path…

This study looks at whether screening adults with leukemia for social needs (like housing or food) and offering early social work help is practical and helpful. About 80 newly diagnosed patients will either get the screening and consultation or usual care. The goal is to see if t…

This study aims to create a simple, objective test to detect nerve damage caused by the chemotherapy drug vincristine in children and teens. Researchers will use a new device to measure nerve function and compare it to standard assessments. The goal is to help doctors adjust chem…

This study compares three ways to image the lungs of infants: CT scans, electrical impedance tomography (EIT), and lung ultrasound. The goal is to see how well the non-invasive methods (EIT and ultrasound) match up with CT in detecting collapsed or overinflated lung areas. Ten in…

This study investigates the long-term heart and lung health of adults who survived childhood acute lymphoblastic leukemia (ALL) or lymphoma. Researchers use advanced MRI and other imaging to detect subtle damage from past chemotherapy, comparing survivors to healthy volunteers. T…

This study enrolls children and teens (ages 1-18) newly diagnosed with certain types of leukemia or lymphoma. The main goal is to gather enough information from their tumor samples to figure out their risk of the cancer coming back, so they can be placed into the right treatment …

This study follows adults aged 18 and older who have a specific type of acute lymphoblastic leukemia (Ph+ ALL) and are receiving a combination of targeted drugs (BCR::ABL1 inhibitors) along with chemotherapy, steroids, or antibody therapy. Researchers will track how long patients…

This study tests a mobile app called ADAPTS designed to help teenagers and young adults with leukemia remember to take their oral chemotherapy. The app sends personalized messages based on the user's mood, pain, or location. The goal is to see if the app is easy to use and accept…

This study collects extra blood and bone marrow samples from people receiving CAR-T cell therapy for lymphoma or acute lymphoblastic leukemia. The goal is to build a biobank that researchers can use to investigate why about half of patients do not respond to this treatment. Parti…

This study will follow 6,000 children, adolescents, and young adults with cancer in low- and middle-income countries. Researchers will collect data from medical records and questionnaires to understand why treatment failure and severe side effects are more common in these setting…

This study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid. It includes 30 children and young adults with blood cancers who already take venetoclax this way. The goal is to measure drug levels in the blood and spinal fluid to ensure t…

This study collects saliva samples from 500 people with newly diagnosed acute lymphoblastic leukemia to look for genetic markers linked to liver damage from the drug asparaginase. The goal is to better understand why some patients develop liver problems during treatment. No new d…

This study follows 1,400 children and teens (ages 3-21) in Southern Europe with acute lymphoblastic leukemia or certain brain tumors. Researchers will track their diet, lifestyle, and quality of life over time to see how these factors relate to treatment side effects and survival…

This study is creating a collection of blood and bone marrow samples from 1,000 adults with acute myeloid leukemia, acute lymphoblastic leukemia, or high-risk myelodysplastic syndrome. The samples will be used by researchers to better understand these diseases and find new ways t…

This study looks at how often children with leukemia or lymphoma develop a shortage of natural stress hormones after high-dose steroid treatment. Researchers will test 40 children during and after therapy to see how long the deficiency lasts and who is most at risk. The goal is t…

This study is testing whether a new wireless skin sensor system can safely and accurately monitor the heart rate, breathing, oxygen levels, and temperature of healthy newborns right after birth. 600 babies will wear both the wireless sensors and standard wired monitors for the fi…

This study tests whether a special PET scan (18F FLT) can detect signs of leukemia or myeloma after treatment. About 60 people aged 4 to 80 with relapsed or hard-to-treat blood cancers will get the scan before and after therapy. Researchers will compare the scan results with stan…

This study aims to create a computer model that predicts how the drug Erwinase behaves in the body of children and young adults with acute lymphoblastic leukemia (ALL). By analyzing data from about 475 patients, researchers hope to find the best doses to kill cancer cells while a…

This study gathers basic health information from 2000 people receiving stem cell transplants for blood cancers or immune disorders. The goal is to track survival and complications to help doctors and researchers improve future treatments. Participants must be getting a standard t…

This study collects stored cord blood from 300 children diagnosed with leukemia and checks for the same cancer mutations found in their tumor samples. Researchers want to understand how and when these mutations first appear before birth. The goal is to eventually develop a screen…

This study looks at how the steroid dexamethasone, used to treat childhood acute lymphoblastic leukemia, affects bone density and the nervous system. Researchers will measure drug levels in blood and spinal fluid, and track bone loss and nerve-related side effects. The goal is to…

This study looks at how the chemotherapy drug calaspargase pegol (Cal-PEG) affects blood clotting in children with acute lymphoblastic leukemia (ALL). Researchers will take blood samples before and after treatment to measure changes in coagulation. The goal is to better understan…

This study tracks how often patients being treated with recombinant Erwinia asparaginase (Rylaze) for blood cancers develop high ammonia levels, a condition called hyperammonemia. Researchers will measure ammonia in the blood of 10 children and teens during their first two treatm…

This study is collecting genetic and drug sensitivity data from 300 children with leukemia to better understand why some cases relapse and how to target them more precisely. Researchers will analyze tumor DNA, gene activity, and test drugs on patient cells in the lab. The goal is…

This study creates a registry of Amish and Mennonite people who want to take part in future medical research. It does not test any treatment or drug. Instead, it builds a list of volunteers so researchers can contact them about studies that match their health and family history. …

This study is observing 500 Indian children with acute lymphoblastic leukemia (ALL) to see how their genes influence treatment side effects and how well they respond to therapy. Researchers will track side effects and measure early response to steroids. The goal is to better unde…

This study follows 173 children aged 8 to 17 with acute lymphoblastic leukemia who are receiving a chemotherapy drug called vincristine. Researchers will measure nerve damage at several points during treatment and look for factors like symptoms, nutrition, sleep, and activity tha…

This study is looking at whether certain carbohydrates in food, called FODMAPs, are related to graft-versus-host disease (GVHD) in people who have had a bone marrow transplant. GVHD is a common complication where donor cells attack the patient's body. Researchers will track 100 t…

This study looks at whether detecting leftover leukemia stem cells in the blood or bone marrow after chemotherapy can better predict if a child's leukemia will come back. About 283 children with newly diagnosed acute myeloid leukemia will be followed. The goal is to improve relap…

This study looks at how metabolism in cancer and immune cells influences the bone marrow environment and treatment resistance in blood cancers like leukemia and myelofibrosis. Researchers will analyze samples from 350 participants to measure metabolites, lipids, and gene activity…

This study will look back at the medical records of 18,000 children, teens, and young adults with cancer treated in five low- and middle-income countries. The goal is to measure how often treatment fails or causes serious side effects, especially for leukemia and lymphoma. No new…

This study creates a registry of 5,000 adults aged 50 and older with blood cancers like multiple myeloma and lymphoma. Researchers will track frailty, muscle loss, and other age-related health issues to better understand this group's needs. The goal is to gather information that …

This study looks at bone marrow cells from children with acute leukemia and compares them to cells from children without blood diseases. The goal is to understand why some leukemias relapse or resist treatment. Researchers will measure how these cells use energy and handle stress…

This study is recruiting 90 people aged 8-25 who are survivors of childhood leukemia, chronic lung disease of prematurity, or heart transplant, plus healthy controls. Researchers will use non-invasive exercise tests to measure heart and lung function during physical activity. The…

This study collects blood, tissue, and body fluid samples from up to 15,000 people with blood cancers or related disorders. The samples are stored in a central lab for future research on diagnosis, prognosis, and immune monitoring. Participants do not receive any treatment as par…

This study follows 1,000 people who previously received an experimental cell therapy (TSC-100 or TSC-101) for blood cancers like leukemia. Researchers will track side effects and survival for up to 15 years to see if the treatment remains safe and effective over time. No new trea…

This study looks at whether CAR-T cell therapy, a new immunotherapy for blood cancers like leukemia and lymphoma, can cause early heart problems. Researchers will measure heart function with ultrasound before and a few days after treatment in 60 patients. The goal is to find out …